Pathology: mHNSCC - L1 - PDL1 positive;
| mHNSCC - L1 - PDL1 positive | |||||
| KEYNOTE-048 (P vs C ; CPS > 20), 2019 | KEYNOTE-048 (P vs C ; CPS > 1), 2019 | KEYNOTE-048 (PC vs C ; CPS > 1), 2019 | KEYNOTE-048 (PC vs C ; CPS > 20), 2019 | ||
| pembrolizumab alone | 2 | T1 | T1 | ||
| pembrolizumab plus 5FU plus platin | 2 | T1 | T1 | ||
| cetuximab plus platin plus 5FU | 0 | T0 | T0 | T0 | T0 |